{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fquadshot-news-podcast.simplecast.com%2Fepisodes%2F11132023-preopanc-2-qw1B4Z5n","width":444,"version":"1.0","type":"rich","title":"11.13.2023 - PREOPANC-2","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/d4956b26-f7a3-4f47-a83d-9293649d65c8/ec08e780-4e06-4c01-8109-4e894d682296/qs_sqaure.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/0bb7e12e-8c9b-4645-9b46-101a308bdb2e\" height=\"200\" width=\"100%\" title=\"11.13.2023 - PREOPANC-2\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Check out this week's QuadCast as we highlight recent reporting from ESMO on best approach to potentially resectable pancreatic cancer, optimal timing of post-op radiosurgery for resected brain mets, the efficacy of dostarlimab on mismatch repair deficient tumors, and more."}